V

Velocity Clinical Research | Durham, NC

Research site

(Unclaimed)

Location

300 East Main Street Suite 200, Durham, North Carolina, United States of America

Site insights

Top conditions

Top treatments

RGT001-075

Ezetimibe

PEOZ-apomorphine

JATENZO®

Obicetrapib

Seltorexant

SER-252

Quetiapine XR

Parent organization

This site is a part of Velocity Clinical Research

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 8 total trials

A Phase 4 Study to Evaluate Adrenal Function in Hypogonadal Men Treated With JATENZO® for 12 Months

TOL-CLAR-20024 is a Phase 4, multi-center, open-label safety study evaluating the potential effect of JATENZO on adrenal function in hypogonadal men...

Active, not recruiting

Hypogonadism

Drug: Jatenzo

A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome (RUBENS)

This study will be a placebo-controlled, double-blind, randomized, Phase 3 study to evaluate the efficacy, safety, and tolerability of obicetrapib 10...

Enrolling

Type 2 Diabetes (T2DM)

Metabolic Syndrome (MetS)

Drug: Obicetrapib 10 mg

Other: Placebo

Randomized Study in Children and Adolescents With Migraine: Acute Treatment

The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in chil...

Enrolling

Pediatric Migraine

Drug: Rimegepant/BHV3000

Drug: Matching placebo

SAD Study in Patients With Parkinson's Disease and Motor Fluctuations

This is a randomized, placebo-controlled, single ascending dose (SAD) study of SER-252 in participants with Parkinson's Disease (PD) and motor fluctu...

Enrolling

Advanced Parkinson's Disease

PARKINSON DISEASE (Disorder)

Drug: SER-252 (PEOZ-apomorphine)

Device: enFuse

Study of Once-Daily Oral RGT001-075 Compared With Placebo in Adults With Obesity or Are Overweight With Weight-Related Health Conditions (COMO-1)

This is a phase 2, 36-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the safety, tolerability, weight loss...

Active, not recruiting

Obesity or Overweight

Drug: Placebo Comparator

Drug: RGT001-075